Answer
Belantamab mafodotin (Blenrep) can cause embryo-foetal harm through its cytotoxic component MMAF and may cross the placenta, so it is not recommended during pregnancy unless the maternal benefit outweighs potential foetal risks.
Sources for this answer
- Blenrep 100mg & 70 mg powder for concentrate for solution for infusionGlaxoSmithKline UK · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked